Chemours (CC) Projected to Release Quarterly Earnings on Tuesday

Chemours (NYSE:CC) is projected to issue its Q2 2026 results after the market closes on Tuesday, August 4th. Analysts expect Chemours to post earnings of $0.4964 per share and revenue of $1.6545 billion for the quarter. Investors may review the information on the company’s upcoming Q2 2026 earning report for the latest details on the call scheduled for Wednesday, August 5, 2026 at 8:00 AM ET.

Chemours (NYSE:CC) last released its quarterly earnings results on Tuesday, May 5th. The specialty chemicals company reported $0.05 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.10. The business had revenue of $1.38 billion during the quarter, compared to the consensus estimate of $1.40 billion. Chemours had a negative net margin of 6.82% and a positive return on equity of 52.49%. The business’s quarterly revenue was up 1.0% compared to the same quarter last year. During the same quarter last year, the company earned $0.13 earnings per share. On average, analysts expect Chemours to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.

Chemours Stock Down 2.8%

Shares of NYSE:CC opened at $16.64 on Friday. The firm has a market cap of $2.50 billion, a PE ratio of -6.30 and a beta of 1.41. The company has a fifty day simple moving average of $19.84 and a 200 day simple moving average of $19.99. The company has a current ratio of 1.82, a quick ratio of 0.87 and a debt-to-equity ratio of 18.98. Chemours has a 12-month low of $10.44 and a 12-month high of $28.67.

Chemours Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 16th. Shareholders of record on Sunday, May 17th were issued a dividend of $0.0875 per share. This represents a $0.35 annualized dividend and a yield of 2.1%. The ex-dividend date of this dividend was Friday, May 15th. Chemours’s dividend payout ratio (DPR) is currently -13.26%.

Analyst Upgrades and Downgrades

CC has been the subject of several research analyst reports. Zacks Research raised shares of Chemours from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, July 21st. Morgan Stanley increased their price objective on Chemours from $17.00 to $21.00 and gave the stock an “equal weight” rating in a report on Monday, May 11th. Truist Financial lifted their target price on Chemours from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Tuesday, April 28th. UBS Group raised their price target on Chemours from $29.00 to $30.00 and gave the company a “buy” rating in a report on Friday, May 8th. Finally, Royal Bank Of Canada increased their target price on shares of Chemours from $26.00 to $29.00 and gave the company an “outperform” rating in a research report on Monday, May 11th. One equities research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, Chemours presently has an average rating of “Moderate Buy” and an average price target of $24.10.

Institutional Investors Weigh In On Chemours

Several hedge funds and other institutional investors have recently bought and sold shares of CC. Cooper Creek Partners Management LLC bought a new stake in Chemours during the third quarter worth approximately $63,103,000. Scopia Capital Management LP increased its holdings in shares of Chemours by 71.7% in the second quarter. Scopia Capital Management LP now owns 3,355,261 shares of the specialty chemicals company’s stock valued at $38,418,000 after buying an additional 1,401,539 shares in the last quarter. State Street Corp increased its holdings in shares of Chemours by 22.7% in the second quarter. State Street Corp now owns 6,114,328 shares of the specialty chemicals company’s stock valued at $70,009,000 after buying an additional 1,131,682 shares in the last quarter. Sona Asset Management US LLC lifted its position in shares of Chemours by 176.9% during the 4th quarter. Sona Asset Management US LLC now owns 1,651,275 shares of the specialty chemicals company’s stock valued at $19,469,000 after acquiring an additional 1,055,000 shares during the last quarter. Finally, Goldman Sachs Group Inc. lifted its position in shares of Chemours by 36.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,701,294 shares of the specialty chemicals company’s stock valued at $43,638,000 after acquiring an additional 996,012 shares during the last quarter. 76.26% of the stock is currently owned by institutional investors.

Chemours Company Profile

Chemours Company, established in 2015 as a spin-off from E. I. du Pont de Nemours and Company, is a global chemistry organization headquartered in Wilmington, Delaware. Since its formation, Chemours has focused on delivering performance chemicals that help customers lower their carbon footprint, increase energy efficiency and conserve water. The company operates with a commitment to safety, environmental stewardship and innovation.

Chemours’ principal business activities are organized into three core segments.